However, in patients with Her-2-positive breast cancers, if there are concurrently low levels of CLDN9, a combination of Her-2 inhibitor and chemotherapies may offer benefits to the patient; a clinical study would be highly valuable to confirm this. This evidence concerns the gene ERBB2 and breast cancer.